Outcomes of renin‐angiotensin inhibitors following transcatheter aortic valve implantation
Key Points:
- Investigates the effects of renin-angiotensin system (RAAS) inhibitors on survival, hemodynamics, and cardiac remodeling post-TAVI.
- Analyzes clinical trial data and real-world evidence to assess benefits and potential risks.
- Provides insights for cardiologists and researchers on optimizing pharmacological therapy after valve replacement.
Description
Outcomes of Renin-Angiotensin Inhibitors Following Transcatheter Aortic Valve Implantation explores the impact of RAAS inhibitors on patient outcomes after TAVI. This comprehensive analysis evaluates their role in cardiovascular protection, post-procedural recovery, and long-term prognosis.
Be the first to review “Outcomes of renin‐angiotensin inhibitors following transcatheter aortic valve implantation”
Reviews
There are no reviews yet.